Vision Mission & Strength
R & D
Niprolac Oral Sol
Starcal D Forte
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
Broculyt(Ambroxol Hydrochloride) is the active metabolite of bromhexine and it has been proven that this metabolite possesses a greater bronchosecretolytic effect than bromhexine. It liquefies the mucus in the lumen of respiratory tract, thus facilitates the expectoration of mucus and reduces dyspnoea. It stimulates production of phospholipids of surfactant by alveolar cells, thus contributing to the lowering of superficial tension in the alveoli. It also reduces bronchial hyperactivity. Owing to the inhibitory effect on the production of cellular cytokines and arachidonic acid metabolites, Ambroxol has anti-inflammatory properties.